MYLS22 |
Catalog No.GC60260 |
MYLS22 est un inhibiteur sélectif de l'atrophie optique 1 (OPA1) de premier ordre.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 306959-01-3
Sample solution is provided at 25 µL, 10mM.
MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor. MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression[1].
MYLS22 (10 mg/kg/die; peritumoral injection; every 2 days for 14 days) causes the tumor growth curtailed mice[1]. Animal Model: 6-week-old C57BL6/J mice with B16F10 melanomas[1]
[1]. StÉphanie Herkenne, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8.
Average Rating: 5
(Based on Reviews and 31 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *